Pricing & Reimbursement

 

Pricing & Reimbursement, Wednesday 24 April 2024

Dean Suhr
Pricing & Reimbursement
11:24

Chair's Remarks

Marshall Summar
Pricing & Reimbursement
11:25

Strategies to save time and cost in rare disease drug development

Marshall Summar, Chief Executive Officer, Uncommon Cures
Kyle Clifton
Pricing & Reimbursement
11:45

Potential for optimal patient access and reimbursement

Panel discussion
Pricing & Reimbursement
12:05

Pricing, reimbursement and payer challenges for rare diseases in the US

Moderator: Durhane Wong-Rieger, President, Chief Executive Officer & Chair, Canadian Organisation for Rare Disorder & Rare Diseases International
Kristin Viswanathan Wolff, Senior Director, Global Government Affairs And Public Policy, bluebird bio
Panel discussion
Pricing & Reimbursement
12:45

Innovative financing solutions for rare disease treatments: Balancing cost, access, and sustainability

Moderator: Mark Trusheim, Strategic Director NEWDIGS, Center for Biomedical System Design, Tufts Medical Center
Steven Peskin, President and Chief Executive Officer; Former Executive Medical Director Population Health, Horizon Blue Cross Blue Shield of NJ, SRP Advisors, LLC
Alexander Natz
Pricing & Reimbursement
15:00

Pricing challenges for rare diseases in Europe

Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Jin Ding
Pricing & Reimbursement
15:40

The growing divergence in orphan approvals: A retrospective cohort study comparing the FDA and the EMA from 2011 to 2020

Panel discussion
last published: 25/Apr/24 19:55

 

 

Get Involved At World Orphan Drug Congress USA

 

To Sponsor Or Exhibit

 
 

Justin Franks
justin.franks@terrapinn.com
t/ +1 914 819 3506

 

 

 

To Speak

 
 

Gina McHugh
gina.mchugh@terrapinn.com
t/ +1 646 619 1775

 

 

 

Marketing & Press Opportunities

 
 

Kaylie Brogan
kaylie.brogan@terrapinn.com